Tg Therapeutics (TGTX) Liabilities and Shareholders Equity (2010 - 2026)

Tg Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 132.81% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $4.3 billion, a 94.44% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 84.05% from the prior year.
• Liabilities and Shareholders Equity rose to $1.5 billion in Q1 2026 per TGTX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q1 2026 and bottomed at $193.6 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $373.3 million (2024), against an average of $527.0 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 49.01% in 2022 and jumped 132.81% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $193.6 million in 2022, then soared by 70.27% to $329.6 million in 2023, then soared by 75.28% to $577.7 million in 2024, then surged by 84.05% to $1.1 billion in 2025, then jumped by 43.79% to $1.5 billion in 2026.
• Per Business Quant, the three latest TGTX Liabilities and Shareholders Equity figures stand at $1.5 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025).